Drugs / SarCNU
SarCNU
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00004079 | Aug 1999 → Sep 2005 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00003703 | Jan 1999 → Mar 2004 | cancer of unknown primary site | Jewish General Hospital | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00036660 | Jan 2002 → Apr 2003 | central nervous system neoplasm | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT00028015 | Oct 2001 → Sep 2003 | colorectal cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SarCNU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003703 ↗ |
| Known as | 2-[{[(2-chloroethyl)(nitroso)amino]carbonyl}(methyl)amino]acetamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL166937 ↗ |
| Known as | 2-Chloroethyl-3-sarcosinamide-1-nitrosourea | “2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) is a novel chloroethylnitrosourea that demonstrates selective cytotoxicity in athymic mice bearing human glioma.” PMID 12525514 ↗ Jan 2003 |
| Known as | NSC 364432 | “A Phase II Study of Second-Line SarCNU (NSC 364432) in Patients With Recurrent/Metastatic Colorectal Cancer” NCT00028015 ↗1“A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma” NCT00036660 ↗ |
| Known as | sarcosinamide nitrosourea | “Patients receive oral sarcosinamide nitrosourea (SarCNU) on days 1, 5, and 9.” NCT00004079 ↗ |
| Known as | Sarmustine | ChEMBL registry synonym — accepted as the source's own label CHEMBL166937 ↗ |
| Modality | Small molecule | “SarCNU is a novel chloroethylnitrosourea” PMID 12525514 ↗ Jan 2003 |
| Route | Oral | “SarCNU was administered orally on days 1,5, and 9 every 28 days.” PMID 12525514 ↗ Jan 2003 |